# An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D

> **NCT05565248** · PHASE1 · TERMINATED · sponsor: **CRISPR Therapeutics AG** · enrollment: 5 (actual)

## Conditions studied

- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Glucose Metabolism Disorders
- Metabolic Disease
- Endocrine System Diseases
- Autoimmune Diseases
- Immune System Diseases

## Interventions

- **COMBINATION_PRODUCT:** VCTX211

## Key facts

- **NCT ID:** NCT05565248
- **Lead sponsor:** CRISPR Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-20
- **Primary completion:** 2025-08-08
- **Final completion:** 2025-08-08
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Patients to be followed up in the VCTX-201 study
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05565248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05565248, "An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05565248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*